Krka (KRK) Q4 2025 earnings summary

Executive summary

• Achieved record revenue of €2,041 million in 2025, up 7% year-on-year, surpassing €2 billion for the first time, with strong growth in most key markets, especially East Europe.

• Net profit reached an all-time high of €401 million, up 13% year-on-year, with a net margin of 19.7%, driven by improved product mix and positive FX effects.

• Launched 17 new products, mainly single-pill combinations and prescription pharmaceuticals, and completed over 900 marketing authorisation procedures.

• Over 19 billion finished products manufactured annually, serving more than 100 million people worldwide.

• Maintained leadership in prescription medicines, accounting for over 83% of total sales.

Financial highlights

• EBITDA margin reached 27.4% (€559 million), up 7% year-on-year, exceeding strategic forecasts and prior year results.

• EBIT margin was 22.8% (€466 million), up 9% year-on-year.

• Earnings per share rose to €13.14, up 13% year-on-year.

• Net financial result positively impacted by FX movements, totaling €28.5 million.

• Dividend payout of €252 million, with a policy to allocate at least 50% of annual profits to dividends.

Outlook and guidance

• 2026 sales projected at €2,144 million (+5% year-on-year), with net profit planned at €405 million.

• CapEx to increase to over €140 million in 2026, focused on production, R&D, and infrastructure upgrades.

• Strategic plan targets average annual sales growth of at least 5% and average EBITDA margin above 25% for 2026–2030.

• Net profit growth expected to average 5.6% over the last five years.

• Confident in continued robust profitability, cash generation, and growth.